Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

NEXT STORY
SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The Lancet
PREV STORY
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ORYZON Updates on New Activities

author_avatar
NASDAQ Market News

Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic ...

author_avatar
NASDAQ Market News

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

author_avatar
NASDAQ Market News